Filing Details

Accession Number:
0000899243-20-032234
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-11-25 21:54:46
Reporting Period:
2020-11-24
Accepted Time:
2020-11-25 21:54:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1743881 Bridgebio Pharma Inc. BBIO Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1758363 Cameron Turtle C/o Bridgebio Pharma, Inc.
421 Kipling Street
Palo Alto CA 94301
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-11-24 4,258 $17.00 16,826 No 4 M Direct
Common Stock Disposition 2020-11-24 4,258 $47.00 12,568 No 4 S Direct
Common Stock Acquisiton 2020-11-25 742 $17.00 13,310 No 4 M Direct
Common Stock Disposition 2020-11-25 742 $47.23 12,568 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-11-24 4,258 $0.00 4,258 $17.00
Common Stock Stock Option (Right to Buy) Disposition 2020-11-25 742 $0.00 742 $17.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
263,742 2029-06-26 No 4 M Direct
263,000 2029-06-26 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020.
  2. Represents the weighted average sale price of the shares sold from $47.00 to $47.04 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3.
  3. Represents the weighted average sale price of the shares sold from $47.03 to $47.32 per share.
  4. The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date.